« Return to News | Ethics/Regulatory

Pew Health urges Congress to reauthorize PDUFA

Monday, February 6, 2012 08:38 AM

Allan Coukell, director of medical programs at the Pew Health Group, issued a statement concerning a U.S. House energy and commerce subcommittee on health hearing on the reauthorization of the Prescription Drug User Fee Act (PDUFA IV), which has shortened the pharmaceutical approval process by the FDA.

"Many Americans would be surprised by the rapid and profound changes in how our prescription drugs are made and the new risks that have arisen as a result. Increased outsourcing and reliance on foreign suppliers have made pharmaceutical manufacturing more difficult to manage and have created opportunities for substandard medicines to reach patients,” said Coukell. “The FDA estimates that 80% of active ingredients used in U.S. drugs come from overseas. Despite the shift of U.S. pharmaceutical manufacturing to overseas, government oversight is overwhelmingly domestically focused.”

Coukell continued, "The reauthorization of the Prescription Drug User Fee Act and passage of other new user-fee programs offer an opportunity for Congress to tackle the risks of the global supply chain. Now it is time for this committee to act on what it has learned over the past four years since the last reauthorization of PDUFA.”

PDUFA IV, which expires Sept. 30, 2012, authorizes the FDA to collect fees from companies that produce certain human drug and biological products.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.